Next Phase Newsletter

The strategic venture capital fund of large pharmaceutical company focuses on investments in companies developing pioneering bioelectronic medicines and technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The fund is looking to invest in 5 to 7 companies over the next five years. The fund is looking for investment opportunities globally.

The fund is currently looking for new investment opportunities in the Biotech R&D and Medical Technology spaces. The fund focuses on two types of companies, those developing implantable devices targeting neuromodulation of the peripheral nervous system and those developing technologies that improve neuromodulation, such as miniaturized devices, enhanced batteries, etc. The firm is looking for companies generally in the pre-clinical stage of development although companies with in-human data are also open for review.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Private Equity firm based in Western Europe controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment and is also highly interested in the in-licensing of early stage assets and technologies. The firm has an 8 year period to exit and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France.  For in-licensing opportunities the firm is willing to look globally.

 The firm is currently most interested in companies developing Therapeutics and Medical Devices and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has strong interest in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space the firm has a strong preference for investing in cardiovascular devices but considers other opportunities as well. The firm looks to invest in very early stages of company development generally when lead assets are preclinical and technologies are still in development.

The firm looks to make seed investments as well as being involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An international life science investment group based in the eastern US is looking to invest invests in life science companies by using its product development and CRO services effectively as a capital investment. The firm has the ability to leverage 30-70% of the development cost in exchange for equity, downstream royalties, etc. The firm places a strong emphasis in the technology and will invest in companies that are based in the USA, UK, Europe, The Middle East, and Asia. The firm is actively seeking new investment opportunities. 

The firm is currently seeking to invest in biotech therapeutics, diagnostics, and medical devices. For therapeutics, the firm seeks both biologics and small molecule assets that are in pre-clinical through to phase III of clinical trials. For medical devices, the firm is also opportunistic in terms of subsectors and only invests in companies with at least a prototype that is ready for clinic. The firm is open to all indications including orphan indications.

The life science venture investment arm of a leading global Private Equity firm with over $50 billion in AUM, is looking to make investments across development pipeline, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $50M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, personalized medicine, diagnostics, industrial biotechnology, healthcare services and IT. The firm does not invest in medical devices. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics. 

The firm invests for the long term, and are heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

A Private Equity firm based in the western United States The firm is currently making investments out of its vintage 2014 healthcare centric fund. The firm looks to make primarily growth equity investments ranging from $5-$30 million with most investments falling in the $10-$30 million dollar range. The firm is willing to review opportunities from around the Globe.

The firm currently interested broadly in the healthcare space including Medical Technology, Therapeutics, Diagnostics, Laboratory Equipment, Healthcare IT and R&D services. For medical technology the firm is looking for companies that have at least an alpha prototype and have some efficacy data.  For companies working with therapeutics the firm is looking for assets that are in Phase II of clinical trials and will only consider companies in Phase I if they have efficacy data. The firm generally does not look for companies in the cardiovascular space and they are open to orphan indications. The firm is also open to investing in companies that have products already on the market.

The firm looks for a strong management team to be in place and is open to invest in both private and publically held companies. For companies that are privately held the firm generally looks to take a board seat.

The corporate venture capital arm of a large tech company is currently seeking to invest the in intersection of software and biology. The fund invests in companies at a variety of developmental stages and investments therefore vary widely, but typically range from $1-10m of equity. The firm is looking for opportunities globally.

Within the medical technology sector, the firm is interested in the intersection between communication and health, and particularly in technologies that improve delivery of patient care and make care more cost-effective.  Areas of focus include traditional healthcare IT (particularly data and communications in a hospital setting), personalized medicine, mobile health technology (including connected medical devices, consumer apps, and patient monitoring technologies that can be used both inside and outside hospitals), and genomic platforms that provide actionable information for patient care (technologies used purely for gene sequencing are not of interest).  While it is not an area of primary focus, connected lab equipment may also be of interest.

The firm invests only in privately-held companies. The firm backs innovative, creative entrepreneurs with expertise in their fields, and who are developing solutions that will have an impact on the health marketplace.

An angel group with offices throughout the United States is looking for companies with female founder or CEO, or with women in other C-level positions. The group prefers to invest in companies with a valuation under $5 million; the group’s first-round equity investments generally range from $ 0.25 million to $2 million. The group invests in companies based across the US and Canada.

The group is currently looking for new investment opportunities in the life science space.  Within the life science sector, the group is highly opportunistic and inclusive when considering opportunities. The group will consider any indication or technology, but as they prefer to invest in products that have an addressable market of over $1 billion, the group is more interested in large marketplaces such as the cardiovascular space than in rare diseases.

In terms of validation, the group prefers to invest in device companies with positive in vitro data and ideally in vivo data; diagnostic companies with strong retrospective and ideally prospective, data; and therapeutics companies with data showing efficacy in animal models.  As the group is interested in products with a shorter path to market, the group primarily invests in healthcare IT (including software-based diagnostic platforms) and medical devices.

The group only backs privately held companies in which women occupy key roles as managers, founders or equity owners, and prefers to back management teams with a strong scientific background.  The group is looking for life science companies with protectable IP, articulated pathways for regulatory and payer approval, clear milestones, and in which the amount of capital required to reach the marketplace can be clearly stated.